Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Christy J. Wilson

Christy J. Wilson

Sr. Director, Pharma and Biotech Segment

Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter

About the author: Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution. Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market. Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).

Posts by Christy J. Wilson

Approaches for creating a COVID-19 vaccine

Posted on March 16th, 2020 in COVID-19

Before the coronavirus disease 2019 (COVID-19) pandemic, no one had ever heard of the causative agent 2019 novel coronavirus (SARS-Cov-2). There were no approved antivirals or vaccines for this virus or for any related coronaviruses (e.g., severe acute respiratory syndrome–associated coronavirus (SARS-CoV) or Middle East respiratory syndrome coronavirus).


Pharma execs discuss drug pricing at JPM2020

Posted on January 27th, 2020 in Pharma R&D

I’ve found lately that drug and treatment pricing pressure is an absolutely unavoidable topic in the industry. It has been highlighted even more recently due to the fact that this pressing issue is often mentioned by the candidates currently running for president in our upcoming election here in the United States. Knowing how important healthcare costs are to many Americans, most of the presidential hopefuls have been promising that they will use the government to bring down prices if they are elected.


Interesting trends, but not many mergers, discussed at JPM2020

Posted on January 22nd, 2020 in Pharma R&D

The annual J.P. Morgan Healthcare Conference took place last week in San Francisco, from January 12-16. While the event continues to be the premiere gathering for heavy-hitters in pharma and biotech, unlike so many past years, this one wasn’t characterized by big M&A announcements. It is not a sign of a slowing down of mergers, considering that, according to FiercePharma, “2019 featured $357 billion worth of deals, breaking a record set back in 2014”. More likely, it is just a sign of our digitally-driven, 24-hour news cycle world that companies are less likely to wait until JPM to make their most important announcements.


Cannibidiol is All the Rage – Is Pharma Getting in on the CBD Craze?

Posted on August 14th, 2019 in Pharma R&D

Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?


  1. 1
  2. 2
  3. 3
  4. …
  5. 13